AI Article Synopsis
- The study evaluated treatment responses in 18 Kaposi sarcoma patients treated with radiotherapy (RT) over an 8-year period, focusing on both subjective and visual responses after treatment.
- Results showed a significant number of patients reported a complete (62.5%) or partial (30%) response, with a noteworthy higher response in males and in patients receiving a specific treatment dosage of 20 Gy in 5 fractions.
- The findings suggest that RT is an effective local treatment for Kaposi sarcoma but highlight the need for further studies to standardize dosages and improve treatment techniques.
Article Abstract
Purpose: The aim of this study is to evaluate the treatment responses of Kaposi sarcoma patients treated with radiotherapy (RT).
Materials And Methods: The data of 18 patients (40 different regions) who were treated for Kaposi sarcoma in OOOO between March 23, 2010 to February 13, 2018 were evaluated retrospectively. The primary endpoint of the study was the clinical-subjective response after RT, and the secondary endpoint was the visual response assessment after RT.
Results: In evaluating the patients' reported response of the lesions: 25 (62.5%) of complete response (CR), 12 (30%) of partial response (PR), and stable response was seen in 3 patients (7.5%). Patient reported response after RT was significantly higher in male sex (p = 0.002; odds ratio [OR] = 13.8, 95% confidence interval [CI], 2.7-70.0). Physician reported response rates were available for 28 lesions and CR was detected in 12 lesions (30%); PR was observed in 16 (40%). The relationship between physician reported outcome and RT techniques (electron, bolus, or water bolus) is close to the limit of statically significance (p = 0.052). Fewer lesions disappeared in patients with photon preference than electrons (p = 0.036; OR = 0.093; 95% CI, 0.009-0.950). Patients' reported complete response rates were significantly higher in the 20 Gy per 5 fractions treatment arm (p = 0.042; OR = 1.75; 95% CI, 1.1-2.7).
Conclusion: RT is an effective local treatment with high response rates in the treatment of Kaposi sarcoma. The subjective-clinical response rate was higher in male sex and the visual response was higher in the 20 Gy per 5 fractions arm. Additional studies are needed to standardize RT dose and techniques.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024179 | PMC |
| http://dx.doi.org/10.3857/roj.2020.00885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Unique Case of Metastatic Oral Kaposi Sarcoma in an HIV-Negative Patient.
Ear Nose Throat J
January 2025
Department of Otolaryngology-Head & Neck Surgery, Lehigh Valley Health Network, Allentown, PA, USA.
Kaposi's sarcoma (KS) is a tumor involving blood vessels and lymphatic tissue. It is caused by human herpes virus-8, typically in HIV infection in individuals with AIDS. There are 4 major types of KS including classic, endemic, immunosuppression, and AIDS-related.
View Article and Find Full Text PDF25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024.
Iran Biomed J
December 2024
Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Neonatal Cutaneous Vascular Anomalies.
Neoreviews
January 2025
Vascular Anomalies Center, Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, Colorado.
Vascular anomalies are broadly classified into 2 categories: vascular tumors and vascular malformations. Vascular anomalies frequently present as cutaneous lesions in infants. This review summarizes vascular anomalies that most commonly present as dermatologic lesions in the neonatal period, with a focus on the clinical findings, pathophysiology and histology, relevant radiographic findings, and management of common vascular anomalies such as infantile hemangiomas, congenital hemangiomas, and Kaposiform hemangioendothelioma, along with vascular malformations, including capillary, lymphatic, venous, and arteriovenous malformations.
View Article and Find Full Text PDFRNA Modifications and Their Role in Regulating KSHV Replication and Pathogenic Mechanisms.
J Med Virol
January 2025
Microbiology Department, University of Massachusetts, Amherst, Massachusetts, USA.
Kaposi's sarcoma-associated herpesvirus is an oncogenic gammaherpesvirus that plays a major role in several human malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. The complexity of KSHV biology is reflected in the sophisticated regulation of its biphasic life cycle, consisting of a quiescent latent phase and virion-producing lytic replication. KSHV expresses coding and noncoding RNAs, including microRNAs and long noncoding RNAs, which play crucial roles in modulating viral gene expression, immune evasion, and intercellular communication.
View Article and Find Full Text PDFAlterations in Cellular Gene Expression Due to Co-Infection With Kaposi's Sarcoma-Associated Herpesvirus and SARS-CoV-2: Implications for Disease Severity.
J Med Virol
January 2025
Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 pandemic, has resulted in over 7 million confirmed deaths. In addition to severe respiratory and systematic symptoms, several comorbidities increase the risk of fatal outcomes. Therefore, it is essential to investigate the impact of COVID-19 on pre-existing conditions in patients, such as cancer and other infectious diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!